Print Page     Close Window     

Corporate Profile
Cipher Pharmaceuticals is a growing specialty pharmaceutical dermatology company, with a robust and diversified portfolio of commercial and early to late-stage products. Through multiple transactions, Cipher has built its U.S. commercial presence, expanded its Canadian dermatology franchise and broadened its pipeline. Cipher is well-capitalized to drive long-term, sustained earnings growth by leveraging its proven clinical development capabilities and efficient commercial execution.

CIPHER PHARMACEUTICALS ANNOUNCES PLANS TO VOLUNTARILY DELIST FROM NASDAQ

ExchangeTSX (Canadian Dollar)
PriceCan$4.31
Change (%) Stock is Down 0.04 (0.92%)
Volume977
Data as of 04/21/17 3:56 p.m. ET
Refresh quote
Recent NewsMore >>
DateTitle 
04/12/17Cipher Pharmaceuticals Proposes Adding Robert Tessarolo and Arthur Deboeck to Board of DirectorsPrinter Friendly Version
04/03/17Cipher Pharmaceuticals Announces Amendment to Debt Agreement and Partial PrepaymentPrinter Friendly Version
03/20/17Cipher Pharmaceuticals Appoints Robert D. Tessarolo as CEOPrinter Friendly Version
Featured Documents
Download Documentation 2016 Annual Report
Download Documentation Q4 2016 MD&A
Download Documentation Q4 Financial Statements
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Cipher Pharmaceuticals Inc posts new information to the site. Just enter your e-mail address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources